Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Continuous lenalidomide-dexamethasone (Rd)-based regimens are among the standards of care in transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients. The oral proteasome inhibitor ixazomib is suitable for continuous dosing, with predictable, manageable toxicities. In the double-blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Facon, Thierry, Venner, Christopher P., Bahlis, Nizar J., Offner, Fritz, White, Darrell J., Karlin, Lionel, Benboubker, Lotfi, Rigaudeau, Sophie, Rodon, Philippe, Voog, Eric, Yoon, Sung-Soo, Suzuki, Kenshi, Shibayama, Hirohiko, Zhang, Xiaoquan, Twumasi-Ankrah, Philip, Yung, Godwin, Rifkin, Robert M., Moreau, Philippe, Lonial, Sagar, Kumar, Shaji K., Richardson, Paul G., Rajkumar, S. Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462404/
https://www.ncbi.nlm.nih.gov/pubmed/33763699
http://dx.doi.org/10.1182/blood.2020008787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462404/
https://www.ncbi.nlm.nih.gov/pubmed/33763699
http://dx.doi.org/10.1182/blood.2020008787

Ejemplares similares